Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83

When building a watch list of stocks, it’s important to look for those with a high RS Rating. Ultragenyx Pharm (RARE) stock recently achieved an upgrade from 75 to 83 on this scale. The RS Rating compares a stock’s price performance over the last year to that of other stocks. Stocks with an RS Rating above 80 tend to be the best performers. Ultragenyx Pharm stock is currently forming a cup with handle pattern with a potential entry point of 49.93. Last quarter, the biotech company reported 0% EPS growth and 8% sales growth. The stock ranks 214th among its peers in the Medical-Biomed/Biotech industry group, alongside other highly rated stocks like Immunogen (IMGN) and Regeneron Pharmaceuticals (REGN).